Clinical trials
Lung Cancer Screening clinical trials
Below are recruiting lung cancer screening clinical trials, each written for real people, not researchers. We’re tracking 689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06660407RecruitingPhase 2
Grid radiation for advanced lung cancer after immunotherapy
This trial tests a special type of radiation called grid therapy for people with stage IV non-small cell lung cancer that has grown after immunotherapy or chemoimmunotherapy. It aims to see if this approach can help control tumors that are larger than 3 centimeters outside the brain.
Rochester, MinnesotaAges 18 years+ - NCT06868849RecruitingPhase 1/Phase 2
Study of JMT203 for Cancer-Related Weight Loss
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
ZhejiangAges 18 years+ - NCT07165691Recruiting
Lung cancer screening coaching for Hispanic patients
This trial tests a program that helps Hispanic and Latino patients make informed decisions about lung cancer screening. It uses a coaching approach to support you and your doctor in choosing the best next steps.
New Brunswick, New JerseyAges 50–77 - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Springdale, ArkansasAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07176000Recruiting
Lung Cancer Screening Help for Tribal Communities
This study is testing whether a special patient navigator can help more people in tribal communities get screened for lung cancer. If you are a current or recent smoker between 50 and 77, you may be able to join and get support to find out if you need a lung scan.
Auburn, WashingtonAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT04976296Recruiting
Monitoring minimal residual disease after lung cancer surgery
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
Guangzhou, GuangdongAges 18 years+ - NCT05924841RecruitingPhase 2
Study drugs for advanced small cell lung cancer after prior treatments
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
Changchun, JilinAges 18–75 - NCT06352008RecruitingPhase 2
Anlotinib for lung cancer patients with incomplete response after chemo-immunotherapy
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
TianjinAges 18 years+ - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06613009RecruitingPhase 1
New Drug IBI3009 for Advanced Small Cell Lung Cancer
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
Westmead, New South WalesAges 18–75 - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07249879RecruitingPhase 1
CAR-T cell therapy for DLL3-positive small cell lung cancer
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07296809RecruitingPhase 2
SKB500 therapy for small cell lung cancer
This trial tests a new drug called SKB500, given alone or with other treatments, for people with extensive-stage small cell lung cancer that has spread. It may be an option for those who have had little or no prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT06747832Enrolling by invitationEarly Phase 1
INK cells after chemoradiation for small cell lung cancer
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Weifang, Shandong Province, China.Ages 18–75 - NCT05864794Recruiting
Screening brain MRI in advanced lung cancer patients
This trial looks at whether doing an MRI scan of the brain for people with stage IV lung cancer helps in their care. The goal is to find brain issues early (if present) so treatment decisions can be made sooner.
Groningen, Provincie GroningenAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Lung Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer screening?
- Yes. Clin2 currently lists 689 recruiting lung cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.